Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future
Curr Radiopharm. 2023 Nov 3. doi: 10.2174/0118744710262325231025075638. Online ahead of print.ABSTRACTThe low range of alpha particles provides an opportunity to better target cancer cells theoretically leading to the introduction of interesting alpha emitter radiopharmaceuticals including 225Ac, 212Pb, etc. The combination of high energy and short range of alpha emitters differentiates targeted radiotherapy from other methods and reduces unwanted cytotoxicity of the cells around the tumoral tissue. Among interesting alpha emitters candidates for targeted therapy, 211At, one of the radioisotopes with the best optimal decay...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Mobina Rabiei Mahboobeh Asadib Hassan Yousefnia Source Type: research
Formulation and In-vivo Characterization of 177Lu-tin-colloid as a Radiosynovectomy Agent
CONCLUSION: 177Lu-tin-colloid was successfully prepared under optimized reaction conditions with high binding efficiency and radiochemical purity. The radiolabeled colloid was found to be stable in-vitro both in PBS and synovial fluid at room temperature. Serial PCET/CT images revealed that the activity was completely retained within the synovial cavity, with no activity leakage out of the joint until 48 hours after the injection. With the support of the results from further clinical studies, it may be possible for the formulation to enter clinical use.PMID:37937551 | DOI:10.2174/0118744710252994231024064842 (Source: Curre...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Guldem Mercanoglu Goksel Alc ın Yusuf Ozturkmen Tevfik Cermik Source Type: research
Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future
Curr Radiopharm. 2023 Nov 3. doi: 10.2174/0118744710262325231025075638. Online ahead of print.ABSTRACTThe low range of alpha particles provides an opportunity to better target cancer cells theoretically leading to the introduction of interesting alpha emitter radiopharmaceuticals including 225Ac, 212Pb, etc. The combination of high energy and short range of alpha emitters differentiates targeted radiotherapy from other methods and reduces unwanted cytotoxicity of the cells around the tumoral tissue. Among interesting alpha emitters candidates for targeted therapy, 211At, one of the radioisotopes with the best optimal decay...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Mobina Rabiei Mahboobeh Asadib Hassan Yousefnia Source Type: research
Formulation and In-vivo Characterization of 177Lu-tin-colloid as a Radiosynovectomy Agent
CONCLUSION: 177Lu-tin-colloid was successfully prepared under optimized reaction conditions with high binding efficiency and radiochemical purity. The radiolabeled colloid was found to be stable in-vitro both in PBS and synovial fluid at room temperature. Serial PCET/CT images revealed that the activity was completely retained within the synovial cavity, with no activity leakage out of the joint until 48 hours after the injection. With the support of the results from further clinical studies, it may be possible for the formulation to enter clinical use.PMID:37937551 | DOI:10.2174/0118744710252994231024064842 (Source: Curre...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Guldem Mercanoglu Goksel Alc ın Yusuf Ozturkmen Tevfik Cermik Source Type: research
Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future
Curr Radiopharm. 2023 Nov 3. doi: 10.2174/0118744710262325231025075638. Online ahead of print.ABSTRACTThe low range of alpha particles provides an opportunity to better target cancer cells theoretically leading to the introduction of interesting alpha emitter radiopharmaceuticals including 225Ac, 212Pb, etc. The combination of high energy and short range of alpha emitters differentiates targeted radiotherapy from other methods and reduces unwanted cytotoxicity of the cells around the tumoral tissue. Among interesting alpha emitters candidates for targeted therapy, 211At, one of the radioisotopes with the best optimal decay...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Mobina Rabiei Mahboobeh Asadib Hassan Yousefnia Source Type: research
Formulation and In-vivo Characterization of 177Lu-tin-colloid as a Radiosynovectomy Agent
CONCLUSION: 177Lu-tin-colloid was successfully prepared under optimized reaction conditions with high binding efficiency and radiochemical purity. The radiolabeled colloid was found to be stable in-vitro both in PBS and synovial fluid at room temperature. Serial PCET/CT images revealed that the activity was completely retained within the synovial cavity, with no activity leakage out of the joint until 48 hours after the injection. With the support of the results from further clinical studies, it may be possible for the formulation to enter clinical use.PMID:37937551 | DOI:10.2174/0118744710252994231024064842 (Source: Curre...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Guldem Mercanoglu Goksel Alc ın Yusuf Ozturkmen Tevfik Cermik Source Type: research
Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future
Curr Radiopharm. 2023 Nov 3. doi: 10.2174/0118744710262325231025075638. Online ahead of print.ABSTRACTThe low range of alpha particles provides an opportunity to better target cancer cells theoretically leading to the introduction of interesting alpha emitter radiopharmaceuticals including 225Ac, 212Pb, etc. The combination of high energy and short range of alpha emitters differentiates targeted radiotherapy from other methods and reduces unwanted cytotoxicity of the cells around the tumoral tissue. Among interesting alpha emitters candidates for targeted therapy, 211At, one of the radioisotopes with the best optimal decay...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Mobina Rabiei Mahboobeh Asadib Hassan Yousefnia Source Type: research
Formulation and In-vivo Characterization of 177Lu-tin-colloid as a Radiosynovectomy Agent
CONCLUSION: 177Lu-tin-colloid was successfully prepared under optimized reaction conditions with high binding efficiency and radiochemical purity. The radiolabeled colloid was found to be stable in-vitro both in PBS and synovial fluid at room temperature. Serial PCET/CT images revealed that the activity was completely retained within the synovial cavity, with no activity leakage out of the joint until 48 hours after the injection. With the support of the results from further clinical studies, it may be possible for the formulation to enter clinical use.PMID:37937551 | DOI:10.2174/0118744710252994231024064842 (Source: Curre...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Guldem Mercanoglu Goksel Alc ın Yusuf Ozturkmen Tevfik Cermik Source Type: research
Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future
Curr Radiopharm. 2023 Nov 3. doi: 10.2174/0118744710262325231025075638. Online ahead of print.ABSTRACTThe low range of alpha particles provides an opportunity to better target cancer cells theoretically leading to the introduction of interesting alpha emitter radiopharmaceuticals including 225Ac, 212Pb, etc. The combination of high energy and short range of alpha emitters differentiates targeted radiotherapy from other methods and reduces unwanted cytotoxicity of the cells around the tumoral tissue. Among interesting alpha emitters candidates for targeted therapy, 211At, one of the radioisotopes with the best optimal decay...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Mobina Rabiei Mahboobeh Asadib Hassan Yousefnia Source Type: research
Formulation and In-vivo Characterization of 177Lu-tin-colloid as a Radiosynovectomy Agent
CONCLUSION: 177Lu-tin-colloid was successfully prepared under optimized reaction conditions with high binding efficiency and radiochemical purity. The radiolabeled colloid was found to be stable in-vitro both in PBS and synovial fluid at room temperature. Serial PCET/CT images revealed that the activity was completely retained within the synovial cavity, with no activity leakage out of the joint until 48 hours after the injection. With the support of the results from further clinical studies, it may be possible for the formulation to enter clinical use.PMID:37937551 | DOI:10.2174/0118744710252994231024064842 (Source: Curre...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Guldem Mercanoglu Goksel Alc ın Yusuf Ozturkmen Tevfik Cermik Source Type: research
Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future
Curr Radiopharm. 2023 Nov 3. doi: 10.2174/0118744710262325231025075638. Online ahead of print.ABSTRACTThe low range of alpha particles provides an opportunity to better target cancer cells theoretically leading to the introduction of interesting alpha emitter radiopharmaceuticals including 225Ac, 212Pb, etc. The combination of high energy and short range of alpha emitters differentiates targeted radiotherapy from other methods and reduces unwanted cytotoxicity of the cells around the tumoral tissue. Among interesting alpha emitters candidates for targeted therapy, 211At, one of the radioisotopes with the best optimal decay...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Mobina Rabiei Mahboobeh Asadib Hassan Yousefnia Source Type: research
Formulation and In-vivo Characterization of 177Lu-tin-colloid as a Radiosynovectomy Agent
CONCLUSION: 177Lu-tin-colloid was successfully prepared under optimized reaction conditions with high binding efficiency and radiochemical purity. The radiolabeled colloid was found to be stable in-vitro both in PBS and synovial fluid at room temperature. Serial PCET/CT images revealed that the activity was completely retained within the synovial cavity, with no activity leakage out of the joint until 48 hours after the injection. With the support of the results from further clinical studies, it may be possible for the formulation to enter clinical use.PMID:37937551 | DOI:10.2174/0118744710252994231024064842 (Source: Curre...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Guldem Mercanoglu Goksel Alc ın Yusuf Ozturkmen Tevfik Cermik Source Type: research
Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future
Curr Radiopharm. 2023 Nov 3. doi: 10.2174/0118744710262325231025075638. Online ahead of print.ABSTRACTThe low range of alpha particles provides an opportunity to better target cancer cells theoretically leading to the introduction of interesting alpha emitter radiopharmaceuticals including 225Ac, 212Pb, etc. The combination of high energy and short range of alpha emitters differentiates targeted radiotherapy from other methods and reduces unwanted cytotoxicity of the cells around the tumoral tissue. Among interesting alpha emitters candidates for targeted therapy, 211At, one of the radioisotopes with the best optimal decay...
Source: Current Radiopharmaceuticals - November 8, 2023 Category: Radiology Authors: Mobina Rabiei Mahboobeh Asadib Hassan Yousefnia Source Type: research
Design of a New < sup > 99m < /sup > Tc-radiolabeled Cyclo-peptide as Promising Molecular Imaging Agent of CXCR < sub > 4 < /sub > Receptor: Molecular Docking, Synthesis, Radiolabeling, and Biological Evaluation
CONCLUSION: Therefore, the findings indicate this designed radioligand could be used as a potential SPECT imaging agent in highly proliferated CXCR4 receptor tumors.PMID:37921191 | DOI:10.2174/0118744710249305231017073022 (Source: Current Radiopharmaceuticals)
Source: Current Radiopharmaceuticals - November 3, 2023 Category: Radiology Authors: Leila Hassanzadeh Mostafa Erfani Safura Jokar Marjan Shriatpanahi Source Type: research
